AI Tools

AI Patent Landscape Report

Type any drug class, target, or mechanism. Get a 6-section executive landscape report — top players, cliff calendar, strongest defences, most vulnerable patents — grounded in our Orange Book + USPTO database.

Powered by Llama 3 on our patent database (16,724 enriched Orange Book patents, ~3,500 international). Free tier: 2 reports per 24h. Upgrade to Pro for 20/day.

How to query: Use a class name ("PD-1 inhibitors"), a target ("KRAS G12C"), or a mechanism ("GLP-1 receptor agonists"). A junior analyst would take a day or two to produce a comparable report. This takes ~10 seconds.
PD-1 inhibitorsGLP-1 receptor agonistsBTK inhibitorsCDK4/6 inhibitorsKRAS G12C inhibitorsJAK inhibitors
Output: ~400-600 word markdown report with patent numbers + vulnerability scores cited inline.

Landscape report

You've hit today's free limit

Free tier allows 2 landscape reports per 24h. Upgrade to Pro for 20/day, saved report library, and patent watchlist alerts.

View Pro pricing →

What you get

  • The landscape — what the class is, active patent count, average vulnerability, when the first major cliff hits
  • Key players — top assignees by patent count, with exact numbers
  • Cliff calendar — years where multiple patents in the class expire
  • Strongest defences — specific patent numbers with vulnerability under 25
  • Most vulnerable — design-around / IPR opportunities with vulnerability over 70
  • Strategic takeaway — competitive dynamics implications

How it works

Step 1: An LLM expands your query into structured search terms (drug INNs, target proteins, indications). Step 2: We pull every matching patent from our database with classification + vulnerability scores. Step 3: A second LLM call generates the report from those facts only, with a hedge-detection post-validator that rejects outputs containing speculative language ("may", "might", "possibly").

Every cited patent number and vulnerability score is real and links back to the source patent record. Same anti-hallucination pipeline as our drug + company strategic briefs.

Disclaimer: AI-generated reports are decision-support, not legal advice. Coverage is limited to drugs in our database (currently FDA-approved + late-stage NMEs).